Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.90 EPS for the current fiscal year. Synageva BioPharma Corp (NASDAQ:GEVA)stock performance was 5.87% in last session and finished the day at $ 85.40. Traded volume was 206,033 shares in the last session and the average volume of the stock remained 323,619 shares. The beta of the stock remained 0.6. Synageva BioPharma Corp (NASDAQ:GEVA) insider ownership is 0.10%

Auspex Pharmaceuticals Inc (NASDAQ:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000®Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) rose 10.88% to $ 18.92 Friday on volume of 371,284 shares. The intra-day range of the stock was $ 18.38 – 21.36. Auspex Pharmaceuticals Inc (NASDAQ:ASPX)has a market capitalization of $ 446.70 million.

Immunogen (NASDAQ:IMGN) issued its quarterly earnings data on Friday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.17, Analyst Ratings Network reports. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $13.28 million. ImmunoGen, Inc. (NASDAQ:IMGN)’s stock on May 2, 2014 reported a increase 5.26% to the closing price of $ 12.06. Its fifty two weeks range is $ 11.78 – 20.25. The total market capitalization recorded $ 1.03 billion. The overall volume in the last trading session was 1,024,641 shares. In its share capital, ImmunoGen, Inc.(NASDAQ:IMGN) has 85.81 million outstanding shares.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.68) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.87) by $0.19. On average, analysts expect Infinity Pharmaceuticals to post $-3.31 EPS for the current fiscal year and $-2.80 EPS for the next fiscal year. On Friday, shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI)Advanced 5.66% to close the day at $ 9.16. Company’s monthly performance is recorded as -18.94%. Infinity Pharmaceuticals Inc. (NASDAQ:INFI)quarterly revenue growth is -28.72%.